Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT06384950 |
| Other study ID # |
2023-11-005A |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
March 22, 2024 |
| Est. completion date |
March 21, 2025 |
Study information
| Verified date |
April 2024 |
| Source |
Taipei Veterans General Hospital, Taiwan |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Liver cancer is a leading cause of cancer-related deaths in Taiwan, with its onset linked to
factors like chronic liver conditions, cirrhosis, and genetic predispositions. According to
the "Barcelona Clinic Liver Cancer (BCLC)" classification, early-stage liver cancer is
demarcated by stages 0 to A. Upon such diagnosis, both patients and their families often have
numerous questions and concerns, ranging from treatment choices to long-term outcomes. The
research proposes a GPT-3.5-based chatbot to assist these patients by providing timely,
personalized information, aiming to enrich their understanding of the disease and improve
communication between patients and health professionals.
The research methodology employs a Randomized Controlled Trial (RCT) design, dividing
participants into a control cohort receiving standard patient education routine and an
experimental cohort receiving both the AI chatbot and traditional education routine. The
comparative analysis of these cohorts will determine the effectiveness of the AI intervention
in improving patients' health literacy and satisfaction.
Description:
Liver cancer is the second most common cause of cancer-related deaths in Taiwan. Various
factors play a role in its development, such as chronic liver conditions, cirrhosis, viral
infections, alcohol intake, obesity, diabetes, and genetic predispositions, among others.
Based on the "Barcelona Clinic Liver Cancer (BCLC)" system, early-stage liver cancer falls
within stages 0 to A. When faced with an early-stage liver cancer diagnosis, patients and
their relatives frequently express concerns. These may range from the potential effects of
the disease on daily living, evaluating treatment options, potential side effects, costs
involved, the chances of recurrence, and survival rates, to the care required after the
treatment. Addressing these worries often requires extensive explanations and time for the
patients to process the information.
The research proposes using a chatbot built upon the GPT-3.5 language model developed by
OpenAI for patient education services. Such a chatbot would aid early-stage liver cancer
patients navigate the complexities of obtaining relevant information. As an artificial
intelligence technology, the chatbot can offer timely, personalized information and
psychological support. By responding to patients' inquiries, the chatbot can provide a
thorough understanding of basic liver cancer knowledge, its causes, and treatment approaches,
thereby facilitating a deeper comprehension of the early stages of liver cancer and its
treatment regimen. Patients and their relatives can comprehend their condition and treatment
plans, enhancing their conversations with medical staff and promoting a harmonious
doctor-patient relationship.
The research uses a Randomized Controlled Trial (RCT) methodology, dividing patients into a
control group undergoing the conventional patient education routine, and an experimental
group that leverages both the chatbot and traditional education. By comparing selected
outcomes between the two groups, the experiment's effectiveness will be determined.
